2011NACB糖尿病診療的指南和建議
《2011NACB糖尿病診療的指南和建議》內(nèi)容簡(jiǎn)介
The National Academy of Clinical Biochemistry （NACB） has developed evidence-based guidelines on topics related to the practiceof laboratory medicine. These guidelines are updated approximately every 5 years and are available on the NACB Web site （http://www.aacc.org/members/nacb）。 The NACB issued its “Guidelines and Recommendations for Laboratory Analysis in the Diagnosisand Management of Diabetes Mellitus” in 2002 （1）。 These recommendations were reviewed and updated via an evidence-basedapproach, especially in areas in which new evidence has emerged since the 2002 publication. The process of updating guideline rec-ommendations followed the standard operating procedures for preparing, publishing, and editing NACB laboratory medicine practiceguidelines. The key steps are summarized in Fig. 1 and are explained below. The guideline-updating process was designed to fulfillthe methodological quality criteria of the Appraisal of Guidelines for Research and Evaluation （AGREE） II Instrument （2）。
《2011NACB糖尿病診療的指南和建議》內(nèi)容預(yù)覽
STEP 1: Determine the Scope and Key Topics of the Guideline
The scope and purpose of this guideline is primarily to focus on the laboratory aspects of testing in the contexts of type 1 and type2 diabetes mellitus （DM）。 It does not deal with any issues related to the clinical management of DM that are already covered inthe American Diabetes Association （ADA） or WHO guidelines. In January of each year, the ADA publishes in Diabetes Care asupplement entitled “Clinical Practice Recommendations.” This supplement, a compilation of all ADA position statements relatedto clinical practice, is an important resource for healthcare professionals who care for people with DM. The intention of theNACB guideline is to supplement the ADA guidelines and to avoid duplication or repetition of ***rmation. Therefore, it focuseson practical aspects of care to assist in making decisions related to the use or interpretation of laboratory tests during screening,diagnosing, or monitoring of patients with DM.
STEP 2: Determine the Target Group of the Guideline and Establish a MultidisciplinaryGuideline Team
The primary target of these recommendations includes general practitioners, physicians, nurses, and other healthcare practitionersdirectly involved in the care of diabetic patients, as well as laboratory professionals. The guidelines can be used by patients whererelevant （e.g., self-monitoring of blood glucose）， policy makers, and payers for healthcare, as well as by researchers. In addition,the guidelines may advise industry/manufacturers on how to use or develop assays for the laboratory management of DM.The guideline committee included representatives of key stakeholders to whom the recommendations are meant to apply primar-ily. Experts of the guideline team are listed in the guideline （3） and represented the NACB （D.B. Sacks, D.E. Bruns） and the ADA（M.S. Kirkman）。 The guideline committee included clinical experts （G.L. Bakris, A. Lernmark, B.E. Metzger, D.M. Nathan） andlaboratory experts （D.B. Sacks, D.E. Bruns, M. Arnold, A.R. Horvath） whose key area of research and practice is DM. Some members
點(diǎn)擊下載***：《2011NACB糖尿病診療的指南和建議》
本站所注明來源為"愛愛醫(yī)"的文章，版權(quán)歸作者與本站共同所有，非經(jīng)授權(quán)不得轉(zhuǎn)載。
本站所有轉(zhuǎn)載文章系出于傳遞更多信息之目的，且明確注明來源和作者，不希望被轉(zhuǎn)載的媒體或個(gè)人可與我們
聯(lián)系z(mì)lzs@120.net，我們將立即進(jìn)行刪除處理
